Vicuron Pharmaceuticals, Inc. (NASDAQ NM:MICU) der nächste Starter - 500 Beiträge pro Seite

[js200]

06/16/2003 (16:30 ET) Vicuron Pharmaceuticals to Webcast Pipeline Review Meeting on June 18, 2003 - PR Newswire
06/16/2003 (10:22 ET) 52W HIGH: New 52-Wk High for MICU @ $15.210 up2.49% - Knobias
06/11/2003 (13:46 ET) 52W HIGH: New 52-Wk High for MICU @ $14.900 up0.68% - Knobias
06/10/2003 (16:06 ET) 52W HIGH: New 52-Wk High for MICU @ $14.800 up3.42% - Knobias
06/06/2003 (17:10 ET) S-3: MICU Regs Cmn Stk (0.001 par) Max Offering $70M - Knobias


JS200

[js200]

Vicuron Pharmaceuticals to Webcast Pipeline Review Meeting on June 18, 2003

Monday , June 16, 2003 16:30 ET

KING OF PRUSSIA, Pa., Jun 16, 2003 /PRNewswire-FirstCall via COMTEX/ -- Vicuron Pharmaceuticals (Nasdaq: MICU), today announced it will webcast its pipeline review meeting which is scheduled for June 18, 2003 at 12:00 p.m. EDT (9:00 a.m. PDT). During the meeting, Company management will detail Vicuron`s drug development programs, pipeline progress and upcoming milestones.

To access the live Internet broadcast or the subsequent archived recording log on to http://www.vicuron.com/" target="_blank" rel="nofollow ugc noopener">http://www.vicuron.com/ . Please connect to Vicuron`s website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary.

About Vicuron

Vicuron Pharmaceuticals is an international biopharmaceutical company focused on discovering, developing, manufacturing and commercializing vital medicine for seriously ill patients. The company recently filed a New Drug Application with the U.S. Food and Drug Administration for its lead product, anidulafungin, a novel antifungal agent. The company`s other lead product, dalbavancin, a novel intravenous antibiotic for the treatment of serious Gram-positive infections, is in Phase III clinical trials. Vicuron`s versatile research engine integrates industry-leading expertise in functional genomics, natural products discovery, mechanism-based drug design and combinatorial and medicinal chemistry. These approaches are yielding promising novel and next-generation compounds, many of which are in the later stages of preclinical development. In addition, Vicuron has research and development collaborations with leading pharmaceutical companies, such as Pfizer and Novartis.

Forward-Looking Statements

This news release contains forward-looking statements that predict or describe future events or trends. The matters described in these forward-looking statements are subject to known and unknown risks, uncertainties and other unpredictable factors, many of which are beyond Vicuron`s control. Vicuron faces many risks that could cause its actual performance to differ materially from the results predicted by its forward-looking statements, including the possibilities that the Securities and Exchange Commission may delay declaring Vicuron`s registration statement effective, if at all, clinical trials and the results thereof might be delayed, that the timing of the filing of any new drug application might be delayed, that subsequent clinical trials might indicate that a product candidate is unsafe or ineffective, that ongoing proprietary and collaborative research might not occur or yield useful results, that competitors might develop superior substitutes for their products or market them more effectively, that a sales force may not be developed as contemplated and that one or more of its product candidates may not be commercialized successfully. The reports that Vicuron files with the U.S. Securities and Exchange Commission contain a fuller description of these and many other risks to which Vicuron is subject. Because of those risks, Vicuron`s actual results, performance or achievements may differ materially from the results, performance or achievements contemplated by its forward-looking statement. The information set forth in this news release represents management`s current expectations and intentions. Vicuron assumes no responsibility to issue updates to the forward-looking matters discussed in this news release.

SOURCE Vicuron Pharmaceuticals


CONTACT: investors, E. Blair Clark of Burns McClellan, [phone],
or [e-mail], for Vicuron Pharmaceuticals; or media, Ian McConnell
of WeissCom Partners, [phone], for Vicuron Pharmaceuticals

URL: http://www.vicuron.com
http://www.prnewswire.com



Copyright (C) 2003 PR Newswire. All rights reserved.


-0-


ProviderSequenceNumber: 7377

KEYWORD: Pennsylvania
INDUSTRY KEYWORD: MTC
BIO
HEA
SUBJECT CODE: CCA


STOCK SYMBOLS: [(micu)]

JS200

[js200]

Last Trade: 14.990 Change: 0.150 ( +1.011 %)



Previous Close: 14.840 Today`s Open: 14.800



# of Trades: 351 Volume: 78,700



Avg. # of Trades: 488 Avg. Daily Volume: 200,156





Bid: 14.750 Bid Size: 15



Ask: 17.210 Ask Size: 2



Day High: 15.240 Day Low: 14.750



52 Week High: 15.200 52 Week Low: 10.120



Market Cap: 396.43M Dividend: N/A



EPS: -4.61 P/E Ratio: N/A

JS200

[js200]

RAiDAR alerts Learn More About RAiDAR-LT


06/16/2003 (16:30 ET) Vicuron Pharmaceuticals to Webcast Pipeline Review Meeting on June 18, 2003 - PR Newswire



06/16/2003 (10:22 ET) 52W HIGH: New 52-Wk High for MICU @ $15.210 up2.49% - Knobias



06/11/2003 (13:46 ET) 52W HIGH: New 52-Wk High for MICU @ $14.900 up0.68% - Knobias



06/10/2003 (16:06 ET) 52W HIGH: New 52-Wk High for MICU @ $14.800 up3.42% - Knobias



06/06/2003 (17:10 ET) S-3: MICU Regs Cmn Stk (0.001 par) Max Offering $70M - Knobias



06/06/2003 (16:42 ET) Vicuron Files Shelf Registration Statement - PR Newswire



06/06/2003 (16:10 ET) New S-3 just released for MICU - Edgar



06/06/2003 (16:10 ET) New 8-K just released for MICU - Edgar



06/05/2003 (16:22 ET) CLOSER(+): Last 90 Min, MICU Jumps +2.85%; Vol +71% - Knobias



06/05/2003 (07:32 ET) CONF: MICU To Present At Needham Biotech Conference @ 08:30 ET - Knobias



05/30/2003 (12:53 ET) VOLUME(+): MICU Volume 49% > 20-adsv, Stock +3.13% - Knobias



05/28/2003 (13:36 ET) MICU: Short Interest UP 5.0% to 1.5M in May 2003 - Knobias



05/22/2003 (16:22 ET) CLOSER(+): Last 90 Min, MICU Jumps +5.14%; Vol +115% - Knobias



05/22/2003 (15:06 ET) VOLUME(+): MICU Volume 71% > 20-adsv, Stock +9.59% - Knobias



05/19/2003 (13:11 ET) New 8-K just released for MICU - Edgar

JS200

[js200]

.
http://www.investtech.com/nasdaq/ana/micu.htm

JS200

[js200]

06/19/2003 (09:50 ET) RATING(=): Needham Reiterates MICU Rating @ Strong Buy - Knobias
06/19/2003 (08:17 ET) RATING(+): JP Morgan Ups MICU to Overweight from Neutral - Knobias
06/18/2003 (09:02 ET) MICU Management to Host Update Meeting Today @ 12PM ET - Knobias
06/18/2003 (07:30 ET) Vicuron Completes Phase 1 Trial of Novel Topical Antibiotic For the Treatment of Acne - PR Newswire
06/16/2003 (16:30 ET) Vicuron Pharmaceuticals to Webcast Pipeline Review Meeting on June 18, 2003 - PR Newswire


JS200

[js200]

RATING(=): Needham Reiterates MICU Rating @ Strong Buy

Thursday , June 19, 2003 09:50 ET

Issuer: Vicuron Pharmaceuticals, Inc. (NasdaqNM: MICU)
Analyst Firm: Needham & Co.

Ratings Action: REITERATION
Current Rating: Strong Buy

Target Price Action: MAINTAIN
Target Price: $18.00

This rating information was reported by Briefing.com.

JS200

[js200]

.-
http://www.investtech.com/nasdaq/ana/micu.htm

JS200